Champions Oncology Stock Today
| CSBR Stock | USD 10.10 0.05 0.49% |
PerformanceOK
| Odds Of DistressLow
|
Champions Oncology is selling at 10.10 as of the 20th of March 2025; that is 0.49 percent decrease since the beginning of the trading day. The stock's lowest day price was 9.47. Champions Oncology has less than a 12 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of January 2003 | Category Healthcare | Classification Health Care |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey. The company has 13.7 M outstanding shares of which 98.84 K shares are currently shorted by private and institutional investors with about 2.69 trading days to cover. More on Champions Oncology
Moving against Champions Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Champions Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | Ronnie MD | ||||
| Old Names | [iShares VII PLC - iShares MSCI Brazil ETF USD Acc, iShares MSCI Brazil ETF USD Acc, iShares MSCI Brazil UCITS ETF USD (Acc) EUR] | ||||
| Business Concentration | Life Sciences Tools & Services, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Life Sciences Tools & Services, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsChampions Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Champions Oncology's financial leverage. It provides some insight into what part of Champions Oncology's total assets is financed by creditors.
| |||||
Champions Oncology (CSBR) is traded on NASDAQ Exchange in USA. It is located in One University Plaza, Hackensack, NJ, United States, 07601 and employs 210 people. Champions Oncology is listed under Life Sciences Tools & Services category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 139.04 M. Champions Oncology conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. The entity has 13.7 M outstanding shares of which 98.84 K shares are currently shorted by private and institutional investors with about 2.69 trading days to cover.
Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Champions Oncology Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Champions Oncology is $139.04 Million. Champions Oncology retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Champions Ownership Details
Champions Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-12-31 | 26.6 K | |
| Bank Of America Corp | 2024-12-31 | 25.3 K | |
| Cambridge Invest Research Advisors, Inc. | 2024-12-31 | 12.3 K | |
| Mesirow Fin Investmt Mgmt Intl Equity | 2024-12-31 | 12 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 11.5 K | |
| Virtu Financial Llc | 2024-12-31 | 11.1 K | |
| Millennium Management Llc | 2024-12-31 | 10.9 K | |
| Citadel Advisors Llc | 2024-12-31 | 10.9 K | |
| Tower Research Capital Llc | 2024-12-31 | 1.6 K | |
| Battery Management Corp | 2024-12-31 | 2.4 M | |
| Nea Management Company, Llc | 2024-12-31 | 1.7 M |
Champions Oncology Historical Income Statement
Champions Stock Against Markets
Champions Oncology Corporate Management
| Marianna Zipeto | Research Commercial | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Maria Mancini | Chief Operations | Profile | |
| Karin Heidemann | Executive Operations | Profile | |
| Arthur Hanson | Vice Technology | Profile | |
| BS CMAR | Ex Operations | Profile |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.